Previous 10 | Next 10 |
2024-04-23 05:15:48 ET More on related stocks: Novartis Looks To Get Back On Track With Q1 Earnings Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation Nucor: A Solid Start To 2024 Novartis beats top-line and bottom-line...
2024-04-23 01:27:04 ET More on Novartis Novartis Looks To Get Back On Track With Q1 Earnings Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation Novartis: Higher Guidance, Now A Buy FDA requires labeling changes to CAR-T...
2024-04-22 11:42:42 ET More on Novartis Novartis Looks To Get Back On Track With Q1 Earnings Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation Novartis: Higher Guidance, Now A Buy FDA requires labeling changes to CAR-T...
2024-04-19 14:48:33 ET More on Health Care Select Sector SPDR: XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Short interest in S&P 500 health stocks rises, Moderna among ...
2024-04-19 11:02:48 ET Summary Novartis' Q1 outlook appears stable, with expectations of a rebound from a previous quarterly miss, projecting $11.57 billion in revenue. Key drugs like Fabhalta and Cosentyx may drive short-term growth, counteracting potential losses from generic co...
2024-04-19 07:03:48 ET Summary Since my last article, the company's share price has fallen about 10% despite its quarterly revenue growth and achieving significant success in developing experimental drugs. In addition to growing sales of next-generation drugs such as Ngenla, Bosul...
2024-04-19 06:13:03 ET More on Bristol-Myers Squibb, Gilead, etc. Johnson & Johnson: Buy This Bargain Before It's Gone Bristol-Myers Squibb: Market Pessimism Won't Last Forever Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript FDA approves Alvo...
2024-04-18 13:59:29 ET Summary Caribou Biosciences, Inc. is expected to produce results from phase 1 ANTLER study, using CB-010 for the treatment of 2nd-line large B-cell lymphoma patients, at medical meeting Q2 of 2024. Initial dose escalation data from the phase 1 ANTLER study i...
2024-04-18 13:15:50 ET More on TG Therapeutics TG Therapeutics: The Cloud Over Briumvi TG Therapeutics: BRIUMVI Development Could Lead To Great Results TG Therapeutics: Briumvi Growth Story Appears Intact TG Therapeutics jumps after second consecutive quarter...
2024-04-18 07:28:39 ET Summary On April 16, Johnson & Johnson released financial results for the first three months of 2024, which were within my expectations. Tecvayli sales were $133 million in the first quarter of 2024, up 111% year over year. Despite increased competit...
News, Short Squeeze, Breakout and More Instantly...
Novartis AG Company Name:
NVS Stock Symbol:
NYSE Market:
Novartis AG (NYSE:NVS) has reportedly filed a lawsuit to block a Maryland law requiring drugmakers to offer discounts on drugs dispensed by third-p...
On Friday, Novartis AG (NYSE:NVS) released new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective Bruton'...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio PR Newswire In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demons...